BioNTech’s mRNA vaccine for head and neck cancer missed the first of two primary endpoints in a pivotal trial.
endpoints.newsBioNTech’s head and neck cancer vaccine misses first of two goalsBioNTech’s mRNA vaccine BNT113 misses PFS goal in a Phase 2/3 head and neck cancer trial; the study continues toward its overall survival endpoint.
1 repost1 like